Siegbahn A - Search Results

1

Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease.

De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Collet JP, Halvorsen S, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Ricci F, Sibbing D, Siegbahn A, Storey RF, Ten Berg J, Verheugt FW, Weitz JI. De Caterina R, et al. Among authors: siegbahn a. Thromb Haemost. 2016 Apr;115(4):685-711. doi: 10.1160/TH15-09-0703. Epub 2016 Mar 8. Thromb Haemost. 2016. PMID: 26952877 Review.

2

Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.

Toss H, Lindahl B, Siegbahn A, Wallentin L. Toss H, et al. Among authors: siegbahn a. Circulation. 1997 Dec 16;96(12):4204-10. doi: 10.1161/01.cir.96.12.4204. Circulation. 1997. PMID: 9416883 Clinical Trial.

3

Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease.

Ernofsson M, Strekerud F, Toss H, Abildgaard U, Wallentin L, Siegbahn A. Ernofsson M, et al. Among authors: siegbahn a. Thromb Haemost. 1998 Mar;79(3):491-4. Thromb Haemost. 1998. PMID: 9531028 Clinical Trial.

4

Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease.

Toss H, Gnarpe J, Gnarpe H, Siegbahn A, Lindahl B, Wallentin L. Toss H, et al. Among authors: siegbahn a. Eur Heart J. 1998 Apr;19(4):570-7. doi: 10.1053/euhj.1997.0771. Eur Heart J. 1998. PMID: 9597405

5

Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease.

Toss H, Wallentin L, Siegbahn A. Toss H, et al. Among authors: siegbahn a. Am Heart J. 1999 Jan;137(1):72-8. doi: 10.1016/s0002-8703(99)70461-8. Am Heart J. 1999. PMID: 9878938 Clinical Trial.

6

Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.

Oldgren J, Linder R, Grip L, Siegbahn A, Wallentin L. Oldgren J, et al. Among authors: siegbahn a. Eur Heart J. 1999 Nov;20(22):1657-66. doi: 10.1053/euhj.1999.1750. Eur Heart J. 1999. PMID: 10543929 Clinical Trial.

7

Coagulation activity and clinical outcome in unstable coronary artery disease.

Oldgren J, Linder R, Grip L, Siegbahn A, Wallentin L. Oldgren J, et al. Among authors: siegbahn a. Arterioscler Thromb Vasc Biol. 2001 Jun;21(6):1059-64. doi: 10.1161/01.atv.21.6.1059. Arterioscler Thromb Vasc Biol. 2001. PMID: 11397720 Clinical Trial.

8

Blood cell activation, coagulation, and inflammation in men and women with coronary artery disease.

Lindmark E, Wallentin L, Siegbahn A. Lindmark E, et al. Among authors: siegbahn a. Thromb Res. 2001 Aug 1;103(3):249-59. doi: 10.1016/s0049-3848(01)00313-9. Thromb Res. 2001. PMID: 11672587

9

Influence on coagulation activity by subcutaneous LMW heparin as an adjuvant treatment to fibrinolysis in acute myocardial infarction.

Frostfeldt G, Gustavsson G, Lindahl B, Nygren A, Siegbahn A, Wallentin L. Frostfeldt G, et al. Among authors: siegbahn a. Thromb Res. 2002 Feb 1;105(3):193-9. doi: 10.1016/s0049-3848(02)00017-8. Thromb Res. 2002. PMID: 11927123 Clinical Trial.

10

Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease.

Oldgren J, Wallentin L, Grip L, Linder R, Nørgaard BL, Siegbahn A. Oldgren J, et al. Among authors: siegbahn a. Eur Heart J. 2003 Jan;24(1):86-93. doi: 10.1016/s0195-668x(02)00312-3. Eur Heart J. 2003. PMID: 12559940 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

328 results

Search Page